



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

AUSTEDO™ (deutetrabenazine) oral INGREZZA™ (valbenazine) oral Tetrabenazine oral XENAZINE® (tetrabenazine) oral

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

AUSTEDO™ (deutetrabenazine) oral INGREZZA™ (valbenazine) oral Tetrabenazine oral XENAZINE® (tetrabenazine) oral

form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

Criteria:

AUSTEDO (deutetrabenazine)

- **Criteria for initial therapy: Austedo (deutetrabenazine)** is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with a Psychiatrist or Neurologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of **ONE** of the following:
 - a. Chorea associated with Huntington's disease
 - b. Tardive dyskinesia
 4. **ONE** of the following:
 - a. **For Huntington's disease:**
 - i. Failure, contraindication per FDA label or intolerance to amantadine
 - b. **For Tardive dyskinesia:**
 - i. Discontinue offending drug if clinically appropriate
 - ii. Switch from a first to a second-generation antipsychotic drug if clinically appropriate
 - iii. Failure, contraindication per FDA label or intolerance to clonazepam **OR** amantadine
 - iv. For localized forms of severe tardive dystonia (e.g., cervical dystonia, blepharospasm), failure, contraindication per FDA label or intolerance botulinum toxin injections
 - v. Failure, contraindication per FDA label or intolerance to tetrabenazine (Brand or generic) or Ingrezza (valbenazine)
 5. There are **NO** FDA-label contraindications, such as:
 - a. Suicidal, or untreated/inadequately treated depression
 - b. Hepatic impairment
 - c. Taking reserpine, MAOIs, tetrabenazine (Brand or generic), or Ingrezza (valbenazine)
 6. Individual does not have congenital long QT syndrome, or a history of cardiac arrhythmias associated with QT prolongation

AUSTEDO™ (deutetrabenazine) oral
INGREZZA™ (valbenazine) oral
Tetrabenazine oral
XENAZINE® (tetrabenazine) oral

7. There are no significant interacting drugs

Initial approval duration: Approve for 6 weeks only

➤ **Criteria for continuation of coverage (renewal request): Austedo (deutetrabenazine)** is considered ***medically necessary*** and will be approved when **ALL** of the following criteria are met:

1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with a Psychiatrist or a Neurologist
2. Individual's condition has not worsened while on therapy
 - a. Worsening is defined as:
 - i. Protruding and twisting movements of the tongue
 - ii. Pouting, puckering, or smacking movements of the lips
 - iii. Retraction of the corners of the mouth
 - iv. Bulging of the cheeks
 - v. Chewing movements
 - vi. Blepharospasm
 - vii. Twisting, spreading, and "piano-playing" finger movements
 - viii. Tapping foot movements
 - ix. Dystonic extensor postures of the toes
3. The indication for use is one that requires a longer duration than the usual 6 weeks such as use for tardive dyskinesia
4. Individual has been adherent with the medication
5. Individual has not developed any contraindications or other significant adverse drug effects that may exclude continued use
 - a. Contraindications as listed in the criteria for initial therapy section
 - b. Significant adverse effect such as:
 - i. Neuroleptic malignant syndrome
 - ii. QT prolongation
 - iii. Akathisia, agitation, restlessness and parkinsonism that does not resolve with dose adjustment
 - iv. Emerging or worsening of depression, suicidality, or unusual changes in behavior
6. Individual does not have congenital long QT syndrome, or a history of cardiac arrhythmias associated with QT prolongation



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

AUSTEDO™ (deutetrabenazine) oral INGREZZA™ (valbenazine) oral Tetrabenazine oral XENAZINE® (tetrabenazine) oral

7. There are no significant interacting drugs

Renewal duration: 6 months

➤ Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. **Off-Label Use of Non-cancer Medications**
 2. **Off-Label Use of Cancer Medications**
-

INGREZZA (valbenazine)

➤ **Criteria for initial therapy:** Ingrezza (valbenazine) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:

1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with a Psychiatrist or Neurologist
2. Individual is 18 years of age or older
3. A confirmed diagnosis of tardive dyskinesia and **ALL** of the following:
 - a. Discontinue offending drug if clinically appropriate
 - b. Switch from a first to a second-generation antipsychotic drug if clinically appropriate
 - c. Failure, contraindication per FDA label, or intolerance to clonazepam **OR** amantadine
 - d. For localized forms of severe tardive dystonia (e.g., cervical dystonia, blepharospasm), failure, contraindication per FDA label or intolerance botulinum toxin injections
 - e. Failure, contraindication per FDA label or intolerance to Austedo (deutetrabenazine) or tetrabenazine (brand or generic)
4. Individual does not have congenital long QT syndrome, or a history of cardiac arrhythmias associated with QT prolongation
5. There are no significant interacting drugs

Initial approval duration: 3 months



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

AUSTEDO™ (deutetrabenazine) oral INGREZZA™ (valbenazine) oral Tetrabenazine oral XENAZINE® (tetrabenazine) oral

➤ **Criteria for continuation of coverage (renewal request): Ingrezza (valbenazine)** is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:

1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with a Psychiatrist or Neurologist
2. Individual's condition has not worsened while on therapy
 - a. Worsening is defined as:
 - i. Protruding and twisting movements of the tongue
 - ii. Pouting, puckering, or smacking movements of the lips
 - iii. Retraction of the corners of the mouth
 - iv. Bulging of the cheeks
 - v. Chewing movements
 - vi. Blepharospasm
 - vii. Twisting, spreading, and "piano-playing" finger movements
 - viii. Tapping foot movements
 - ix. Dystonic extensor postures of the toes
3. The indication for use is one that requires a longer duration than the usual 3 months such as use for tardive dyskinesia
4. Individual has been adherent with the medication
5. Individual has not developed any significant adverse drug effects that may exclude continued use
 - a. Significant adverse effect such as:
 - i. Parkinsonism that does not resolve with dose adjustment
 - ii. QT prolongation
6. Individual does not have congenital long QT syndrome, or a history of cardiac arrhythmias associated with QT prolongation
7. There are no significant interacting drugs

Renewal duration: 6 months

➤ Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. **Off-Label Use of Non-cancer Medications**
2. **Off-Label Use of Cancer Medications**

AUSTEDO™ (deutetrabenazine) oral
INGREZZA™ (valbenazine) oral
Tetrabenazine oral
XENAZINE® (tetrabenazine) oral

Tetrabenazine, generic
XENAZINE (tetrabenazine)

- **Criteria for initial therapy:** Xenazine (tetrabenazine) and generic tetrabenazine is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with a Psychiatrist or Neurologist
 2. A confirmed diagnosis of **ONE** of the following:
 - a. Individual is 18 years of age or older diagnosed with chorea associated with Huntington's disease **AND** the following:
 - i. Individual has failure, contraindication per FDA label or intolerance to amantadine
 - b. Individual is 18 years of age or older diagnosed with Tardive Dyskinesia **AND** the following:
 - i. Discontinue offending drug if clinically appropriate
 - ii. Switch from a first to a second-generation antipsychotic drug if clinically appropriate
 - iii. Failure, contraindication per FDA label or intolerance to clonazepam **OR** amantadine
 - iv. For localized forms of severe tardive dystonia (e.g., cervical dystonia, blepharospasm), failure, contraindication per FDA label or intolerance botulinum toxin injections
 - c. Individual is 14 years of age or older diagnosed with Tics due to Tourette's syndrome **AND** the following:
 - i. Individual has failure, contraindication per FDA label or intolerance to **ALL** of the following:
 1. Aripiprazole, fluphenazine, haloperidol, pimozide, and risperidone
 - ii. Individual with concurrent ADHD has failure, contraindication per FDA label or intolerance to the use of both clonidine and guanfacine
 3. **For brand Xenazine:** Individual has failure, contraindication per FDA label or intolerance generic tetrabenazine
 4. There are **NO** FDA-label contraindications, such as:
 - a. Actively suicidal, or who have depression which is untreated or undertreated
 - b. Hepatic impairment
 - c. Taking monoamine oxidase inhibitors (MAOIs) or reserpine
 - d. Taking Austedo (deutetrabenazine) or Ingrezza (valbenazine)
 5. Individual does not have congenital long QT syndrome, or a history of cardiac arrhythmias associated with QT prolongation

AUSTEDO™ (deutetrabenazine) oral
INGREZZA™ (valbenazine) oral
Tetrabenazine oral
XENAZINE® (tetrabenazine) oral

6. There are no significant interacting drugs

Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Xenazine (tetrabenazine) and generic tetrabenazine is considered **medically necessary** and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with a Psychiatrist or Neurologist
 2. Individual's condition is stable or has not worsened while on therapy
 3. Individual has been adherent with the medication
 4. Individual has not developed any contraindications or other significant adverse drug effects that may exclude continued use
 - a. Contraindications as listed in the criteria for initial therapy section
 - b. Significant adverse effect such as:
 - i. Neuroleptic malignant syndrome
 - ii. Akathisia, agitation, restlessness, and parkinsonism that does not resolve with dose adjustment
 - iii. Emerging or worsening of depression, suicidality, or unusual changes in behavior
 - iv. Symptomatic hyperprolactinemia
 5. Individual does not have congenital long QT syndrome, or a history of cardiac arrhythmias associated with QT prolongation
 6. There are no significant interacting drugs

Renewal duration: 12 months

- Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:
1. **Off-Label Use of Non-cancer Medications**
 2. **Off-Label Use of Cancer Medications**



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

AUSTEDO™ (deutetrabenazine) oral
INGREZZA™ (valbenazine) oral
Tetrabenazine oral
XENAZINE® (tetrabenazine) oral

Description:

Austedo (deutetrabenazine) and tetrabenazine (brand Xenazine and generic) are indicated for the treatment of chorea associated with Huntington's disease (HD). The mechanism of the anti-chorea action is unknown but it is believed to be related to depletion of monoamines from nerve terminals. Austedo (deutetrabenazine) and Ingrezza (valbenazine) are indicated for the treatment of adults with tardive dyskinesia (TD). The mechanism of action of deutetrabenazine and valbenazine in the treatment of TD is unknown but is thought to be due to regulation of monoamine uptake from the cytoplasm into the synaptic vesicle for storage and release.

Deutetrabenazine, tetrabenazine, and valbenazine are reversible inhibitors of the vesicle monoamine transporter type 2 (VMAT-2). They inhibit uptake of the neurotransmitter's serotonin, norepinephrine, histamine, and, especially, dopamine into the granular vesicles of presynaptic neurons and ultimately lead to depletion of monoamine stores. Dopamine is a chemical that communicates between certain nerve cells in the brain. In patients with HD, this system is overactive and results in the abnormal movements of chorea. Austedo (deutetrabenazine) and Xenazine (tetrabenazine) decrease the amount of dopamine available to interact with certain nerve cells, thereby decreasing the involuntary movements. Tetrabenazine also exhibits weak binding affinity at the dopamine 2 (D2) receptor. The pathophysiology of TD remains poorly understood, but it is believed to be the result of chronic blockade of dopamine receptors, particularly D2 and possibly D3, by dopamine receptor blocking agents (DRBA). In addition to dopamine, other neurotransmitter receptors may be important, especially 5-hydroxytryptamine 2 (5-HT₂) receptors that modulate motor activity. One of the most prominent theories about TD pathogenesis is that chronic exposure to the neuroleptics results in D2 receptor upregulation with postsynaptic dopamine receptor supersensitivity.

HD is a rare, inherited neurological disorder affecting about 1 in 10,000 people in the United States. The disease results from degeneration and deterioration of brain cells. The deterioration causes uncontrolled movements (chorea), cognitive decline, and psychiatric/behavioral changes. Cognitive symptoms include confusion on time and place, loss of judgment, memory loss, and personality changes. Movement problems include restless leg, fidgeting, facial movements, head turning to shift eye position, jerking of arms, legs, face and other body parts, speech problems, slow uncontrolled movements, swallowing problems, and unsteady gait. As chorea worsens the individual is at risk for falls. Due to swallowing difficulties, HD individuals also have difficulty in maintaining nutrition leading to further declines in functional capacity.

Chorea is an abnormal involuntary movement caused by overactivity of the neurotransmitter dopamine in the areas of the brain that control movement. It is characterized by brief, irregular contractions that are not repetitive or rhythmic, but appear to flow from one muscle to the next. The full spectrum of motor impairment in HD includes eye movement abnormalities, Parkinsonian features and dystonia, myoclonus, tics, ataxia, dysarthria, dysphagia, spasticity with hyperreflexia and extensor plantar responses.

The underlying pathology and neurochemical bases of HD are complex and not fully understood. It is thought that dopamine and glutamate transmission and their interaction with receptors at various sites in the brain are affected.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

AUSTEDO™ (deutetrabenazine) oral

INGREZZA™ (valbenazine) oral

Tetrabenazine oral

XENAZINE® (tetrabenazine) oral

A recent guideline on the treatment of HD published in 2012 from the American Academy of Neurology (AAN) stated that amantadine, tetrabenazine, or riluzole (although its effect is dose dependent) may be used for chorea. Nabilone may have a weak or a slight effect on chorea but long-term information is lacking. Data on use of clozapine, other neuroleptics, or donepezil were not sufficient to make a recommendation for or against their use in the management of chorea.

Tardive dyskinesia (TD) is one of the most well-known types of tardive syndromes (TDS). TD is estimated to affect 500,000 people in the United States. TDS are movement disorders that affect voluntary muscles. In TDS, abnormal body movements occur, and these movements cannot be controlled voluntarily. Classic TD usually involves random rhythmic involuntary movements of the face; affecting the tongue, lips, or jaw where abnormal movement of the jaw is seen as a chewing motion and facial grimacing. Other affected body parts include the hands, arms, legs, fingers, toes, or hips. TDS includes other types of abnormal movements besides TD and includes tardive akathisia, tardive dystonia, tardive myoclonus, tardive tremor, and tardive tics (also known as tardive tourettism).

TD results from chronic (three or more months) exposure to DRBA, some neuroleptics or antipsychotics (typical and atypical agents), tricyclic antidepressants (amoxapine), and antiemetics or other medications used for gastrointestinal disorders (promethazine and metoclopramide). Not all individuals who are using DRBA go on to develop TD. Factors that may contribute to the development of TD include duration of treatment, type of DRBA used, age, alcohol use or use of other substances of abuse, HIV/AIDS, and female gender. The diagnosis of TD is based on the patient's history of exposure to DRBA, characteristic clinical presentation, and exclusion or other conditions such as includes Huntington's disease.

In 2013 the American Academy of Neurology evidence-based guideline on the treatment of TDS stated that clonazepam or ginkgo biloba probably improves TDS, and both should be considered as treatment. The guideline also stated that amantadine and tetrabenazine might be considered as treatment for TDS.

The Gilles de la Tourette syndrome (TS) is a chronic inherited neurological disorder characterized by involuntary motor and phonic tics that wax and wane. Tics are sudden, brief, intermittent movements (motor tics) or utterances (vocal or phonic tics). Tics have been considered involuntary, but tics can temporarily be voluntarily suppressed. The onset of TS is typically between 2-15 years of age. Many individuals with TS also have a variety of comorbid conditions such as obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), learning difficulties, and sleep abnormalities. Tics often decline during adolescence and resolve by age 18 in about one-half of children, although some tics may persist into adulthood, but their severity gradually diminishes over time in another 40-45% of cases.

TS is thought to result from a complex interaction between social and environmental factors and multiple genetic abnormalities. The diagnosis of TS is based on a set of criteria using clinical features of the disease, particularly the presence of multiple motor and vocal tics, with onset before age 18 or 21, the presence of vocal tics, and a family history of similar symptoms.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 7/16/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

AUSTEDO™ (deutetrabenazine) oral INGREZZA™ (valbenazine) oral Tetrabenazine oral XENAZINE® (tetrabenazine) oral

Treatment is indicated when symptoms of TS interfere with social interactions, school or job performance, activities of daily living, or cause subjective discomfort, pain, or injury. Specific treatment should take into account the need to treat the most troublesome symptoms and presence of comorbid conditions such as ADHD, OCD, behavioral problems, and mood disorders. However, there are no well-designed and well-powered clinical studies available to guide treatment selection; the literature provides low level evidence and drugs are often selected by use of expert experience, opinion, and preference.

In 2011 a clinical guideline by the European Society for the Study of Tourette syndrome was published. After reviewing the literature, the evidence supported the use of haloperidol, pimozide, ziprasidone, risperidone (when TS is seen with disruptive behavior disorder), or olanzapine (when TS is seen with obsessive-compulsive behavior). Other antipsychotics have been used in TS and include aripiprazole, fluphenazine, and quetiapine. When TS is seen with ADHD, the evidence supported the use of clonidine or guanfacine. Tetrabenazine was concluded as an alternative to an antipsychotic. Retrospective non-randomized trials of its use in TS showed moderate to marked improvement in function and TS-related symptoms, these results were viewed as encouraging and pointed to a need for further studies.

Resources:

Austedo (deutetrabenazine) product information, revised by Teva Neuroscience, Inc. 06-2021. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed December 28, 2021.

Ingrezza (valbenazine) product information, revised by Neurocrine Biosciences, Inc. 04-2021. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed December 28, 2021.

Xenazine (tetrabenazine) product information, revised by Lundbeck Pharmaceuticals, LLC. 11-2019. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed December 28, 2021.

Tetrabenazine product information, revised by Apotex Corp. 09-2018. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed December 28, 2021.

Suchowersky O. Huntington disease: Management. In: UpToDate, Hurtig HI, Eichler AF (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Topic last updated December 02, 2021. Accessed December 28, 2021.

Liang TW, Tarsy D. Tardive dyskinesia: Prevention, treatment, and prognosis. In: UpToDate, Hurtig HI, Marder S, Eichler AF (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Topic last updated June 16, 2021. Accessed December 28, 2021.

Jankovic J. Tourette syndrome: Management. In: UpToDate, Nordli DR, Eichler AF (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Topic last updated July 09, 2021. Accessed December 28, 2021.